Zhou Ting, He Xiaobo, Fang Wenfeng, Zhan Jianhua, Hong Shaodong, Qin Tao, Ma Yuxiang, Sheng Jin, Zhou Ningning, Zhao Yuanyuan, Huang Yan, Zhang Li
From the Department of Medical Oncology, Sun Yat-Sen University Cancer Center (TZ, XH, WF, JZ, SH, TQ, YM, JS, NZ, YZ, YH, LZ); State Key Laboratory of Oncology in South China (TZ, XH, WF, JZ, SH, TQ, YM, JS, NZ, YZ, YH, LZ); and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (TZ, XH, WF, JZ, SH, TQ, YM, JS, NZ, YZ, YH, LZ).
Medicine (Baltimore). 2016 Mar;95(12):e3097. doi: 10.1097/MD.0000000000003097.
The pretreatment albumin/globulin ratio (AGR) has been used as a prognostic factor in various cancers. This study aimed to evaluate the predictive value of AGR in small-cell lung cancer (SCLC).We tested albumin and total proteins in plasma samples from 276 SCLC patients from our cancer center between January 2003 and December 2006. The AGR was defined by the formula: albumin/(total proteins-albumin). The correlation between AGR and overall survival (OS) was examined by Kaplan-Meier and Cox regression methods. For validation, AGR was used to evaluate the prognosis of SCLC in another independent group.Total 276 patients (testing) and 379 patients (validation) were finally enrolled. The median OS was 15.31 months for testing patients and 15.06 months for validation patients, respectively. We determined 1.29 as the cutoff value by using the biostatistical tool (Cutoff Finder), then the patients in the testing group were classified into 2 groups. Kaplan-Meier curves showed high AGR group had significantly longer OS than low AGR group (P = 0.026). According to multivariate analyses, AGR was an independent prognostic factor for OS of SCLC patients in the testing group (HR, 1.35, 95% CI: 1.01-1.81, P = 0.046). In the validation group, AGR was also verified as a predictive factor for OS (P < 0.001), and the risk of SCLC in the low AGR group was 1.43 times higher than that in the high AGR group (HR, 1.43, 95% CI: 1.05-1.94, P = 0.022).AGR is an independent prognostic marker in SCLC patients. Furthermore, it could be of great value in the management of SCLC patients.
预处理白蛋白/球蛋白比值（AGR）已被用作多种癌症的预后因素。本研究旨在评估AGR在小细胞肺癌（SCLC）中的预测价值。我们检测了2003年1月至2006年12月期间来自我们癌症中心的276例SCLC患者血浆样本中的白蛋白和总蛋白。AGR由公式定义：白蛋白/（总蛋白-白蛋白）。采用Kaplan-Meier和Cox回归方法检验AGR与总生存期（OS）之间的相关性。为了进行验证，AGR被用于评估另一个独立组中SCLC的预后。最终共纳入276例患者（测试组）和379例患者（验证组）。测试组患者的中位OS为15.31个月，验证组患者为15.06个月。我们使用生物统计学工具（Cutoff Finder）确定1.29为临界值，然后将测试组患者分为两组。Kaplan-Meier曲线显示，高AGR组的OS明显长于低AGR组（P = 0.026）。根据多变量分析，AGR是测试组SCLC患者OS的独立预后因素（HR，1.35，95%CI：1.01-1.81，P = 0.046）。在验证组中，AGR也被证实为OS的预测因素（P < 0.001），低AGR组SCLC的风险比高AGR组高1.43倍（HR，1.43，95%CI：1.05-1.94，P = 0.022）。AGR是SCLC患者的独立预后标志物。此外，它在SCLC患者的管理中可能具有重要价值。
